RECRUITING

A Phase I/II Study of Photodynamic Therapy Treatment of Primary Localized Prostate Cancer

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability. The subjects will be followed for a period of 18 months to determine the primary outcome. The long-term follow-up is an additional 18 months, i.e. a total of 36 months. Interstitial Photodynamic Therapy (PDT) will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery.

Official Title

Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer

Quick Facts

Study Start:2025-01-06

Study Completion:2029-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06807359

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:MALE

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subjects ≥ 18 years. 2. Histologically confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including subjects on active surveillance with evidence of disease progression and a prostate biopsy not older than 9 months. 3. Gleason Score 7 (3+4 or 4+3). 4. PSA ≤ 15 ng/mL. 5. Lesion volume on mpMRI \< 1.5 cm3. 6. Adequate stage imaging such as pelvic CT/MRI/PET scan within the last 6 months confirming localized cancer. 7. Treatment target volume \<50 cm3 defined by TRUS or MRI. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 9. Expected survival ≥ 36 months. 10. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3. 11. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl. 12. Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal. 13. Signed Informed Consent.	1. Evidence of locally advanced, regional pelvic lymph node metastasis, or metastatic disease. 2. Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI 3. Contralateral PIRADS 4/5 lesion (even if negative targeted biopsy) 4. High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as \>1 core of GG1 with a linear amount of carcinoma \>6mm. 5. Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate. 6. Prior treatment with any form of brachytherapy. 7. Previous androgen deprivation therapy (ADT) or chemotherapy for prostate cancer. 8. Prior or current bleeding diathesis. 9. Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site. 10. Use of Alpha-reductase inhibitors (ARIs) within 90 days of enrolment. 11. Any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision). 12. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator. 13. Contraindication for photosensitizer including: 1. Porphyria or other diseases exacerbated by light. 2. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients. 3. Known allergies to porphyrins. 14. On-going therapy with a photosensitizing agent. 15. Enrolment in another therapeutic clinical study within 3 month prior to enrolment and throughout the study. 16. Contraindication for MRI/Gadolinium contrast such as: implants, hip prosthesis, severe renal impairment (glomerular filtration rate \[GFR\] \<30 mL/min/1.73m2), or previous contrast reactions. 17. Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium

Inclusion Criteria

Exclusion Criteria

1. Subjects ≥ 18 years.
2. Histologically confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including subjects on active surveillance with evidence of disease progression and a prostate biopsy not older than 9 months.
3. Gleason Score 7 (3+4 or 4+3).
4. PSA ≤ 15 ng/mL.
5. Lesion volume on mpMRI \< 1.5 cm3.
6. Adequate stage imaging such as pelvic CT/MRI/PET scan within the last 6 months confirming localized cancer.
7. Treatment target volume \<50 cm3 defined by TRUS or MRI.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
9. Expected survival ≥ 36 months.
10. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3.
11. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl.
12. Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.
13. Signed Informed Consent.

1. Evidence of locally advanced, regional pelvic lymph node metastasis, or metastatic disease.
2. Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI
3. Contralateral PIRADS 4/5 lesion (even if negative targeted biopsy)
4. High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as \>1 core of GG1 with a linear amount of carcinoma \>6mm.
5. Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate.
6. Prior treatment with any form of brachytherapy.
7. Previous androgen deprivation therapy (ADT) or chemotherapy for prostate cancer.
8. Prior or current bleeding diathesis.
9. Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site.
10. Use of Alpha-reductase inhibitors (ARIs) within 90 days of enrolment.
11. Any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
12. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give informed consent or to complete follow-up visits according to the judgement of the investigator.
13. Contraindication for photosensitizer including:
1. Porphyria or other diseases exacerbated by light.
2. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients.
3. Known allergies to porphyrins.
14. On-going therapy with a photosensitizing agent.
15. Enrolment in another therapeutic clinical study within 3 month prior to enrolment and throughout the study.
16. Contraindication for MRI/Gadolinium contrast such as: implants, hip prosthesis, severe renal impairment (glomerular filtration rate \[GFR\] \<30 mL/min/1.73m2), or previous contrast reactions.
17. Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium

Contacts and Locations

Study Contact

Kristina Holst

CONTACT

+46708233630

clinical@spectracure.com

Principal Investigator

Jonathan Fainberg, MD, MPH

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center, New York, United States

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

United States

Collaborators and Investigators

Sponsor: SpectraCure AB

Jonathan Fainberg, MD, MPH, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center, New York, United States

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-06

Study Completion Date2029-01

Study Record Updates

Study Start Date2025-01-06

Study Completion Date2029-01

Terms related to this study

Additional Relevant MeSH Terms

Prostate Cancer